Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Viking Thera (VKTX)

Viking Thera (VKTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,708,171
  • Shares Outstanding, K 111,436
  • Annual Sales, $ 0 K
  • Annual Income, $ -85,900 K
  • EBIT $ -134 M
  • EBITDA $ -142 M
  • 60-Month Beta 0.88
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.07

Options Overview Details

View History
  • Implied Volatility 98.42% ( +2.31%)
  • Historical Volatility 79.17%
  • IV Percentile 58%
  • IV Rank 41.88%
  • IV High 234.70% on 02/16/24
  • IV Low 0.20% on 02/27/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 29,472
  • Volume Avg (30-Day) 17,007
  • Put/Call OI Ratio 0.26
  • Today's Open Interest 240,832
  • Open Int (30-Day) 212,349

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 12
  • High Estimate -0.22
  • Low Estimate -0.33
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -8.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.80 +11.77%
on 12/18/24
56.25 -24.89%
on 11/26/24
-9.28 (-18.01%)
since 11/20/24
3-Month
37.80 +11.77%
on 12/18/24
81.73 -48.31%
on 10/28/24
-28.22 (-40.05%)
since 09/20/24
52-Week
17.23 +145.21%
on 01/03/24
99.41 -57.50%
on 02/28/24
+24.63 (+139.78%)
since 12/20/23

Most Recent Stories

More News
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck?

The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a result of a new move announced by Merck (NYSE: MRK) .

VKTX : 42.25 (+1.83%)
MRK : 98.05 (-1.48%)
My Top 10 Stocks to Buy for 2025

It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. It's time to look back on your portfolio's performance and plan...

NVDA : 134.70 (+3.08%)
VKTX : 42.25 (+1.83%)
CRWD : 362.29 (+3.21%)
ABT : 114.23 (+1.61%)
ETSY : 56.81 (-0.58%)
VRTX : 397.27 (+0.16%)
AXP : 298.65 (+1.90%)
AMZN : 224.92 (+0.73%)
PFE : 26.36 (+2.29%)
PLTR : 80.55 (+8.54%)
Why Viking Therapeutics Tumbled by More Than 10% This Week

News of a fresh licensing deal by a well-capitalized rival sent Viking Therapeutics (NASDAQ: VKTX) stock into something of a tailspin this week. According to data compiled by S&P Global Market Intelligence,...

VKTX : 42.25 (+1.83%)
NVO : 85.00 (-17.83%)
MRK : 98.05 (-1.48%)
LLY : 767.76 (+1.35%)
Novo Nordisk Heads For Worst Day In 22 Years As New Obesity Drug Underwhelms: Retail Brushes Off ‘Super Silly’ Drop

On the analyst front, Citi and UBS both described Novo’s readout as favorable for Eli Lilly.

VKTX : 42.25 (+1.83%)
NVO : 85.00 (-17.83%)
LLY : 767.76 (+1.35%)
AMGN : 263.38 (+0.84%)
Why Novo Nordisk Stock Got Destroyed Today, but Eli Lilly and Viking Stocks Are Up

Today's sell-off in Novo Nordisk may be the buying opportunity you've been waiting for.

VKTX : 42.25 (+1.83%)
NVO : 85.00 (-17.83%)
LLY : 767.76 (+1.35%)
Viking Therapeutics Stock Slides After Merck Strikes GLP-1 Deal With Chinese Biopharma, Retail Unperturbed

Viking’s own promising oral GLP-1 candidate, VK2735, is currently being studied for obesity and other metabolic conditions.

VKTX : 42.25 (+1.83%)
MRK : 98.05 (-1.48%)
Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030

Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason. Patients need their medications, so regardless of the economic environment, these companies...

VKTX : 42.25 (+1.83%)
VRTX : 397.27 (+0.16%)
LLY : 767.76 (+1.35%)
PFE : 26.36 (+2.29%)
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street

It's been a good year for the stock market as a whole and a tremendous year for a couple of drugmaker start-ups. Shares of Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) more...

VKTX : 42.25 (+1.83%)
WFC : 70.34 (+2.16%)
SMMT : 17.87 (-2.88%)
LLY : 767.76 (+1.35%)
Warning: This Skyrocketing Stock Has a Hidden Risk

One particular healthcare stock has shown its ability to soar on good news -- and it's had plenty of it. This year the company reported solid results from trials of a candidate meant to address one of...

VKTX : 42.25 (+1.83%)
NVO : 85.00 (-17.83%)
LLY : 767.76 (+1.35%)
GS : 566.10 (+2.19%)
2 'Strong Buy' Biotech Stocks With 120% or More Upside Potential

With the growing demand for cutting-edge therapies reshaping the healthcare landscape, here are two “Strong Buy”-rated biotech stocks with significant potential upside.

VKTX : 42.25 (+1.83%)
CRBP : 13.00 (-2.48%)
NVO : 85.00 (-17.83%)
$SPX : 5,930.85 (+1.09%)
LLY : 767.76 (+1.35%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and VK2809 which are in different clinical trial. Viking Therapeutics, Inc. is based in LA...

See More

Key Turning Points

3rd Resistance Point 47.20
2nd Resistance Point 46.10
1st Resistance Point 44.17
Last Price 42.25
1st Support Level 41.15
2nd Support Level 40.05
3rd Support Level 38.12

See More

52-Week High 99.41
Fibonacci 61.8% 68.02
Fibonacci 50% 58.32
Fibonacci 38.2% 48.62
Last Price 42.25
52-Week Low 17.23

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar